ImmunityBio's ANKTIVA Now Available To Patients Through Both Commercial And Government Insurance Programs, Also Announced Plans To Expand Its Bladder Cancer Program Globally, Notably In The European Union And India
ImmunityBio's ANKTIVA Now Available To Patients Through Both Commercial And Government Insurance Programs, Also Announced Plans To Expand Its Bladder Cancer Program Globally, Notably In The European Union And India
ImmunityBio的ANKTIVA現在可以通過商業和政府保險計劃提供給患者，還宣佈計劃在全球範圍內擴大其膀胱癌項目，尤其是在歐盟和印度。
ANKTIVA reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval
ANKTIVA在FDA批准後三個月內達到了美國商業和醫療保險覆蓋的里程碑。
- Global expansion of commercial and clinical bladder cancer programs
- Filing process initiated with European Medicines Agency (EMA) for regulatory approval of ANKTIVA in European Union countries
- Global filing for BCG naïve trial initiated (QUILT-2.005) in India
- ANKTIVA Non-Small Cell Lung Cancer (NSCLC) FDA meeting held in June 2024
- 擴大商業和臨床膀胱癌計劃的全球範圍。
- 已向歐洲藥品管理局（EMA）提出ANKTIVA在歐盟國家的監管批准申請程序。
- 在印度啓動了BCG未接種試驗的全球申報（QUILt-2.005） 。
- 2024年6月舉行了關於ANKTIVA非小細胞肺癌（NSCLC）的FDA會議。
ImmunityBio, Inc. ((IBRX), today announced significant progress in market access, making ANKTIVA (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company also announced plans to expand its bladder cancer program globally, notably in the European Union and India.
ImmunityBio, Inc.（IBRX）今天宣佈，在市場準入方面取得了重大進展，並通過商業和政府保險計劃使ANKTIVA（nogapendekin alfa inbakicept-pmln）廣泛可用於患者，該公司還宣佈計劃在全球範圍內擴展其膀胱癌計劃，尤其是在歐盟和印度。